Clinical trial
Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous…
NCT00428077 · OHSU Knight Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00428077 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia |
| Official title | A Multi-Center Pilot Phase II Trial of a Synthetic Tumor-Specific Breakpoint Peptide Vaccine in Patients With Chronic Myeloid Leukemia (CML) and Minimal Residual Disease |
| Lead sponsor | OHSU Knight Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Genetic |
| Interventions | bcr-abl peptide vaccine, reverse transcriptase-polymerase chain reaction |
| Enrollment | 4 |
| Start date | Oct 1, 2005 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Jan 29, 2007 |
| Last update posted | Sep 2, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: